Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study
[Display omitted] •Real-world SURE programme data complement those from the SUSTAIN clinical trials.•SURE Denmark/Sweden studied local use of once-weekly semaglutide in adults with T2D.•Semaglutide was associated with significant HbA1c and body weight reductions.•No new safety concerns were reported...
Gespeichert in:
| Veröffentlicht in: | Primary care diabetes 2021-10, Vol.15 (5), p.871-878 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 878 |
|---|---|
| container_issue | 5 |
| container_start_page | 871 |
| container_title | Primary care diabetes |
| container_volume | 15 |
| creator | Rajamand Ekberg, Neda Bodholdt, Ulrik Catarig, Andrei-Mircea Catrina, Sergiu-Bogdan Grau, Katrine Holmberg, Cecilia Nagorny Klanger, Boris Knudsen, Søren Tang |
| description | [Display omitted]
•Real-world SURE programme data complement those from the SUSTAIN clinical trials.•SURE Denmark/Sweden studied local use of once-weekly semaglutide in adults with T2D.•Semaglutide was associated with significant HbA1c and body weight reductions.•No new safety concerns were reported.•These data support the clinical use of once-weekly semaglutide in Denmark/Sweden.
As part of the SURE programme, SURE Denmark/Sweden aimed to study the real-world use of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D) in Denmark/Sweden.
SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA1c value ≤12 weeks before initiating semaglutide at their physician’s discretion. Primary (change in HbA1c) and secondary (including change in body weight, glycaemic and weight-loss target achievement) endpoints were assessed between baseline and end of study (EOS).
Of the 331 patients initiating semaglutide, 282 (85%) completed the study on treatment. For the latter, estimated mean changes [95% confidence interval] in HbA1c and body weight between baseline and EOS were –1.2 [–1.3; –1.1]%-points (–13 [–14; –12] mmol/mol) and –5.4 [–6.0; –4.7] kg (both p < 0.0001), respectively, with similar results in Denmark and Sweden. At EOS, 67.5% of patients achieved HbA1c |
| doi_str_mv | 10.1016/j.pcd.2021.06.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_460954</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1751991821001121</els_id><sourcerecordid>2546596996</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-9c78873cb5f96e34300cff50d3afcae4206f08419228b928048c6bd798b1960e3</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEoh_wA7ggHzmQrZ04jg0nVMqHVAlpS8-WY0-od_OF7Wy0f4bf2ql2W05w8nj8vO_YnsmyN4yuGGXiYrOarFsVtGArKlaUymfZKZO1zDFDn2NcVyxXismT7CzGDaWClbJ-mZ2UnMmyEOo0-7MG0-XLGDpH5ghkbMk4WMgXgG23JxF686ubk3dA_EAmkzwMKZLFpzuS9hOQgjhvGkgQP5A1xLnD0zaMPUl3QG5u11fkMwy9CduLmwUcDKRHxFt0CfCeTGGME9jkd7gZmwhhhyXGwXQkptntX2UvWtNFeH1cz7PbL1c_L7_l1z--fr_8dJ1bLnnKla2lrEvbVK0SUPKSUtu2FXWlaa0BXlDRUsmZKgrZqEJSLq1oXK1kw5SgUJ5n-cE3LjDNjZ6Cxzvv9Wi8Pqa2GIHmgqqKI6_-yeOb3F_Ro5DxWnDORYnadwctgr9niEn3PlroOjPAOEddVFxUSiglEGUH1OI_xQDtUyFG9cMI6I3GEdAPI6Cp0DgCqHl7tJ-bHtyT4rHnCHw8AIAfuvMQdLTYVQvOB2yFdqP_j_09k2zFWw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2546596996</pqid></control><display><type>article</type><title>Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study</title><source>MEDLINE</source><source>SWEPUB Freely available online</source><source>Access via ScienceDirect (Elsevier)</source><creator>Rajamand Ekberg, Neda ; Bodholdt, Ulrik ; Catarig, Andrei-Mircea ; Catrina, Sergiu-Bogdan ; Grau, Katrine ; Holmberg, Cecilia Nagorny ; Klanger, Boris ; Knudsen, Søren Tang</creator><creatorcontrib>Rajamand Ekberg, Neda ; Bodholdt, Ulrik ; Catarig, Andrei-Mircea ; Catrina, Sergiu-Bogdan ; Grau, Katrine ; Holmberg, Cecilia Nagorny ; Klanger, Boris ; Knudsen, Søren Tang</creatorcontrib><description>[Display omitted]
•Real-world SURE programme data complement those from the SUSTAIN clinical trials.•SURE Denmark/Sweden studied local use of once-weekly semaglutide in adults with T2D.•Semaglutide was associated with significant HbA1c and body weight reductions.•No new safety concerns were reported.•These data support the clinical use of once-weekly semaglutide in Denmark/Sweden.
As part of the SURE programme, SURE Denmark/Sweden aimed to study the real-world use of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D) in Denmark/Sweden.
SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA1c value ≤12 weeks before initiating semaglutide at their physician’s discretion. Primary (change in HbA1c) and secondary (including change in body weight, glycaemic and weight-loss target achievement) endpoints were assessed between baseline and end of study (EOS).
Of the 331 patients initiating semaglutide, 282 (85%) completed the study on treatment. For the latter, estimated mean changes [95% confidence interval] in HbA1c and body weight between baseline and EOS were –1.2 [–1.3; –1.1]%-points (–13 [–14; –12] mmol/mol) and –5.4 [–6.0; –4.7] kg (both p < 0.0001), respectively, with similar results in Denmark and Sweden. At EOS, 67.5% of patients achieved HbA1c <7%; 49.4% achieved a weight reduction of ≥5%. Reported adverse events were consistent with the known safety profile of semaglutide.
In routine clinical practice in Denmark/Sweden, use of OW semaglutide was associated with glycaemic and weight-loss benefits in a wide range of adults with T2D, supporting real-world use.
NCT03648281.</description><identifier>ISSN: 1751-9918</identifier><identifier>ISSN: 1878-0210</identifier><identifier>EISSN: 1878-0210</identifier><identifier>DOI: 10.1016/j.pcd.2021.06.008</identifier><identifier>PMID: 34183269</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Body weight ; Denmark ; Diabetes Mellitus, Type 2 - diagnosis ; Diabetes Mellitus, Type 2 - drug therapy ; Glucagon-like peptide-1 receptor agonist ; Glucagon-Like Peptides - therapeutic use ; Glycated Hemoglobin A - analysis ; HbA1c ; Humans ; Hypoglycemic Agents - therapeutic use ; Medicin och hälsovetenskap ; Prospective Studies ; Real-world evidence ; Semaglutide ; SURE study ; Sweden ; Treatment Outcome ; Type 2 diabetes</subject><ispartof>Primary care diabetes, 2021-10, Vol.15 (5), p.871-878</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-9c78873cb5f96e34300cff50d3afcae4206f08419228b928048c6bd798b1960e3</citedby><cites>FETCH-LOGICAL-c484t-9c78873cb5f96e34300cff50d3afcae4206f08419228b928048c6bd798b1960e3</cites><orcidid>0000-0001-5597-2593 ; 0000-0002-7020-6157 ; 0000-0003-4662-0945 ; 0000-0002-7667-8315</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pcd.2021.06.008$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,315,553,781,785,886,3551,27926,27927,45997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34183269$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:147644463$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Rajamand Ekberg, Neda</creatorcontrib><creatorcontrib>Bodholdt, Ulrik</creatorcontrib><creatorcontrib>Catarig, Andrei-Mircea</creatorcontrib><creatorcontrib>Catrina, Sergiu-Bogdan</creatorcontrib><creatorcontrib>Grau, Katrine</creatorcontrib><creatorcontrib>Holmberg, Cecilia Nagorny</creatorcontrib><creatorcontrib>Klanger, Boris</creatorcontrib><creatorcontrib>Knudsen, Søren Tang</creatorcontrib><title>Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study</title><title>Primary care diabetes</title><addtitle>Prim Care Diabetes</addtitle><description>[Display omitted]
•Real-world SURE programme data complement those from the SUSTAIN clinical trials.•SURE Denmark/Sweden studied local use of once-weekly semaglutide in adults with T2D.•Semaglutide was associated with significant HbA1c and body weight reductions.•No new safety concerns were reported.•These data support the clinical use of once-weekly semaglutide in Denmark/Sweden.
As part of the SURE programme, SURE Denmark/Sweden aimed to study the real-world use of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D) in Denmark/Sweden.
SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA1c value ≤12 weeks before initiating semaglutide at their physician’s discretion. Primary (change in HbA1c) and secondary (including change in body weight, glycaemic and weight-loss target achievement) endpoints were assessed between baseline and end of study (EOS).
Of the 331 patients initiating semaglutide, 282 (85%) completed the study on treatment. For the latter, estimated mean changes [95% confidence interval] in HbA1c and body weight between baseline and EOS were –1.2 [–1.3; –1.1]%-points (–13 [–14; –12] mmol/mol) and –5.4 [–6.0; –4.7] kg (both p < 0.0001), respectively, with similar results in Denmark and Sweden. At EOS, 67.5% of patients achieved HbA1c <7%; 49.4% achieved a weight reduction of ≥5%. Reported adverse events were consistent with the known safety profile of semaglutide.
In routine clinical practice in Denmark/Sweden, use of OW semaglutide was associated with glycaemic and weight-loss benefits in a wide range of adults with T2D, supporting real-world use.
NCT03648281.</description><subject>Adult</subject><subject>Body weight</subject><subject>Denmark</subject><subject>Diabetes Mellitus, Type 2 - diagnosis</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Glucagon-like peptide-1 receptor agonist</subject><subject>Glucagon-Like Peptides - therapeutic use</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>HbA1c</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Medicin och hälsovetenskap</subject><subject>Prospective Studies</subject><subject>Real-world evidence</subject><subject>Semaglutide</subject><subject>SURE study</subject><subject>Sweden</subject><subject>Treatment Outcome</subject><subject>Type 2 diabetes</subject><issn>1751-9918</issn><issn>1878-0210</issn><issn>1878-0210</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNp9kk1v1DAQhiMEoh_wA7ggHzmQrZ04jg0nVMqHVAlpS8-WY0-od_OF7Wy0f4bf2ql2W05w8nj8vO_YnsmyN4yuGGXiYrOarFsVtGArKlaUymfZKZO1zDFDn2NcVyxXismT7CzGDaWClbJ-mZ2UnMmyEOo0-7MG0-XLGDpH5ghkbMk4WMgXgG23JxF686ubk3dA_EAmkzwMKZLFpzuS9hOQgjhvGkgQP5A1xLnD0zaMPUl3QG5u11fkMwy9CduLmwUcDKRHxFt0CfCeTGGME9jkd7gZmwhhhyXGwXQkptntX2UvWtNFeH1cz7PbL1c_L7_l1z--fr_8dJ1bLnnKla2lrEvbVK0SUPKSUtu2FXWlaa0BXlDRUsmZKgrZqEJSLq1oXK1kw5SgUJ5n-cE3LjDNjZ6Cxzvv9Wi8Pqa2GIHmgqqKI6_-yeOb3F_Ro5DxWnDORYnadwctgr9niEn3PlroOjPAOEddVFxUSiglEGUH1OI_xQDtUyFG9cMI6I3GEdAPI6Cp0DgCqHl7tJ-bHtyT4rHnCHw8AIAfuvMQdLTYVQvOB2yFdqP_j_09k2zFWw</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Rajamand Ekberg, Neda</creator><creator>Bodholdt, Ulrik</creator><creator>Catarig, Andrei-Mircea</creator><creator>Catrina, Sergiu-Bogdan</creator><creator>Grau, Katrine</creator><creator>Holmberg, Cecilia Nagorny</creator><creator>Klanger, Boris</creator><creator>Knudsen, Søren Tang</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0001-5597-2593</orcidid><orcidid>https://orcid.org/0000-0002-7020-6157</orcidid><orcidid>https://orcid.org/0000-0003-4662-0945</orcidid><orcidid>https://orcid.org/0000-0002-7667-8315</orcidid></search><sort><creationdate>20211001</creationdate><title>Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study</title><author>Rajamand Ekberg, Neda ; Bodholdt, Ulrik ; Catarig, Andrei-Mircea ; Catrina, Sergiu-Bogdan ; Grau, Katrine ; Holmberg, Cecilia Nagorny ; Klanger, Boris ; Knudsen, Søren Tang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-9c78873cb5f96e34300cff50d3afcae4206f08419228b928048c6bd798b1960e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Body weight</topic><topic>Denmark</topic><topic>Diabetes Mellitus, Type 2 - diagnosis</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Glucagon-like peptide-1 receptor agonist</topic><topic>Glucagon-Like Peptides - therapeutic use</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>HbA1c</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Medicin och hälsovetenskap</topic><topic>Prospective Studies</topic><topic>Real-world evidence</topic><topic>Semaglutide</topic><topic>SURE study</topic><topic>Sweden</topic><topic>Treatment Outcome</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rajamand Ekberg, Neda</creatorcontrib><creatorcontrib>Bodholdt, Ulrik</creatorcontrib><creatorcontrib>Catarig, Andrei-Mircea</creatorcontrib><creatorcontrib>Catrina, Sergiu-Bogdan</creatorcontrib><creatorcontrib>Grau, Katrine</creatorcontrib><creatorcontrib>Holmberg, Cecilia Nagorny</creatorcontrib><creatorcontrib>Klanger, Boris</creatorcontrib><creatorcontrib>Knudsen, Søren Tang</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Primary care diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rajamand Ekberg, Neda</au><au>Bodholdt, Ulrik</au><au>Catarig, Andrei-Mircea</au><au>Catrina, Sergiu-Bogdan</au><au>Grau, Katrine</au><au>Holmberg, Cecilia Nagorny</au><au>Klanger, Boris</au><au>Knudsen, Søren Tang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study</atitle><jtitle>Primary care diabetes</jtitle><addtitle>Prim Care Diabetes</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>15</volume><issue>5</issue><spage>871</spage><epage>878</epage><pages>871-878</pages><issn>1751-9918</issn><issn>1878-0210</issn><eissn>1878-0210</eissn><abstract>[Display omitted]
•Real-world SURE programme data complement those from the SUSTAIN clinical trials.•SURE Denmark/Sweden studied local use of once-weekly semaglutide in adults with T2D.•Semaglutide was associated with significant HbA1c and body weight reductions.•No new safety concerns were reported.•These data support the clinical use of once-weekly semaglutide in Denmark/Sweden.
As part of the SURE programme, SURE Denmark/Sweden aimed to study the real-world use of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D) in Denmark/Sweden.
SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA1c value ≤12 weeks before initiating semaglutide at their physician’s discretion. Primary (change in HbA1c) and secondary (including change in body weight, glycaemic and weight-loss target achievement) endpoints were assessed between baseline and end of study (EOS).
Of the 331 patients initiating semaglutide, 282 (85%) completed the study on treatment. For the latter, estimated mean changes [95% confidence interval] in HbA1c and body weight between baseline and EOS were –1.2 [–1.3; –1.1]%-points (–13 [–14; –12] mmol/mol) and –5.4 [–6.0; –4.7] kg (both p < 0.0001), respectively, with similar results in Denmark and Sweden. At EOS, 67.5% of patients achieved HbA1c <7%; 49.4% achieved a weight reduction of ≥5%. Reported adverse events were consistent with the known safety profile of semaglutide.
In routine clinical practice in Denmark/Sweden, use of OW semaglutide was associated with glycaemic and weight-loss benefits in a wide range of adults with T2D, supporting real-world use.
NCT03648281.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>34183269</pmid><doi>10.1016/j.pcd.2021.06.008</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-5597-2593</orcidid><orcidid>https://orcid.org/0000-0002-7020-6157</orcidid><orcidid>https://orcid.org/0000-0003-4662-0945</orcidid><orcidid>https://orcid.org/0000-0002-7667-8315</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1751-9918 |
| ispartof | Primary care diabetes, 2021-10, Vol.15 (5), p.871-878 |
| issn | 1751-9918 1878-0210 1878-0210 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_460954 |
| source | MEDLINE; SWEPUB Freely available online; Access via ScienceDirect (Elsevier) |
| subjects | Adult Body weight Denmark Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Glucagon-like peptide-1 receptor agonist Glucagon-Like Peptides - therapeutic use Glycated Hemoglobin A - analysis HbA1c Humans Hypoglycemic Agents - therapeutic use Medicin och hälsovetenskap Prospective Studies Real-world evidence Semaglutide SURE study Sweden Treatment Outcome Type 2 diabetes |
| title | Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T10%3A06%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-world%20use%20of%20once-weekly%20semaglutide%20in%20patients%20with%20type%202%20diabetes:%20Results%20from%20the%20SURE%20Denmark/Sweden%20multicentre,%20prospective,%20observational%20study&rft.jtitle=Primary%20care%20diabetes&rft.au=Rajamand%20Ekberg,%20Neda&rft.date=2021-10-01&rft.volume=15&rft.issue=5&rft.spage=871&rft.epage=878&rft.pages=871-878&rft.issn=1751-9918&rft.eissn=1878-0210&rft_id=info:doi/10.1016/j.pcd.2021.06.008&rft_dat=%3Cproquest_swepu%3E2546596996%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2546596996&rft_id=info:pmid/34183269&rft_els_id=S1751991821001121&rfr_iscdi=true |